The pilot project for chronic kidney disease screening, jointly conducted by the Pirkanmaa wellbeing services county, AstraZeneca Oy, and Fimlab, is on track to meet its set objectives. The aim of the project is to identify kidney disease at an early stage and initiate treatment in a timely manner.

In the screening project, which began in 2024 within the Pirkanmaa wellbeing services county, 8,248 55-year-old residents of the region were invited to participate. A total of 4,018 screening visits were carried out at Fimlab, meaning that 49% of those invited took part. The participation rate meets the project’s target, and the results provide a reliable basis for assessing the effectiveness of early identification of chronic kidney disease through screening.

Among the participants, 5.9 percent had a positive screening result. Diagnosis and treatment for these individuals will continue within primary care in Pirha.

Based on the data collected in the pilot project, a cost-effectiveness calculator is being developed and will be published in autumn 2025. The research project linked to the chronic kidney disease screening registry has received solid funding to accelerate the research work.

Read more about the pilot project: pirha.fi/seulontapilotti

The main implementer of the screening pilot was the Pirkanmaa wellbeing services county. The project partners were Fimlab Laboratoriot Oy and the pharmaceutical company AstraZeneca Oy. AstraZeneca Oy has acted as a partial funder for the development work related to the project. AstraZeneca Oy has not participated in the implementation or funding of general tasks under the responsibility of the Pirkanmaa wellbeing services county, such as conducting or funding laboratory measurements or patient care. AstraZeneca Oy does not participate in the processing of personal data of individuals participating in the screening, and no personal data is transferred to AstraZeneca.